SAM
FDMT icon

Simplify Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Simplify Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-70,430
Closed -$656K – 149
2026
Q1 		$656K Buy
+70,430
New +$613K 0.01% 93

Other funds holding FDMT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Simplify Asset Management's FDMT Position: Q2 2026 in Review

Simplify Asset Management sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 70,430 shares — an estimated $656K sold.

Simplify Asset Management first reported a position in FDMT in Q1 2026 and held it in 1 quarter. The position peaked at $656K in Q1 2026. 9 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Simplify Asset Management reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Simplify Asset Management sold 70,430 4D Molecular Therapeutics shares in Q2 2026, an estimated $656K.
  • Simplify Asset Management first reported a position in 4D Molecular Therapeutics in Q1 2026 and held it in 1 quarter.
  • Simplify Asset Management's 4D Molecular Therapeutics position peaked at $656K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Simplify Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.